Pretransplant Medications and Primary Graft Dysfunction Risk in Lung Transplant Recipients

PurposePrimary graft dysfunction (PGD) is a serious complication of lung transplantation marked by acute injury and reperfusion edema in the immediate post-transplant period, but effect pretransplant medication use on PGD risk not known. We hypothesized that some medications could be associated with risk, particularly those anti-inflammatory activity (macrolide antibiotics, statins) vasoactives (anti-hypertensives, pulmonary vasodilators).MethodsWe reviewed previously published cohort adult patients who underwent transplant our program between 2004 2016. The primary outcome was development grade 3 (PGD3) at 48- or 72-hours post-transplant. assessed classes from listing records, sample these verified against admission records. evaluated relationship class PGD3 using Fisher's exact testing multivariable logistic regression, adjusting for known factors including recipient diagnosis, body mass index, mean arterial pressure, donor age smoking status.Results19% 330 during study timeframe developed PGD3. Phosphodiesterase inhibitor (PDE5i), endothelin receptor antagonist, proton pump inhibitor, beta blocker (BB) showed unadjusted associations PDE5 BB remained after adjustment (table 1). significantly further correction left ventricular end diastolic pressure.ConclusionOur exploratory analysis no association properties - macrolides statins PDE5i increased despite indication, suggestive vasoactive may play role. These would benefit study. Primary vasodilators). status. 19% pressure. Our